Veracyte (VCYT) – Research Analysts’ Recent Ratings Updates

A number of firms have modified their ratings and price targets on shares of Veracyte (NASDAQ: VCYT) recently:

• 9/15/2026 – Veracyte had its “buy” rating reaffirmed by Needham & Company LLC.
• 9/9/2026 – Veracyte was upgraded by Weiss Ratings from “hold (c)” to “hold (c+)”.
• 9/9/2026 – Veracyte had its price target raised by UBS Group AG from $52.00 to $65.00. They now have a “buy” rating on the stock.
• 9/9/2026 – Veracyte had its price target raised by UBS Group AG from $52.00 to $65.00. They now have a “buy” rating on the stock.
• 8/24/2026 – Veracyte was downgraded by Weiss Ratings from “hold (c+)” to “hold (c)”.
• 8/11/2026 – Veracyte was upgraded by Zacks Research from “hold” to “strong-buy”.
• 8/7/2026 – Veracyte was upgraded by Weiss Ratings from “hold (c)” to “hold (c+)”.
• 8/4/2026 – Veracyte had its price target lowered by Piper Sandler from $66.00 to $54.00. They now have an “overweight” rating on the stock.
• 8/4/2026 – Veracyte had its price target lowered by Stephens from $68.00 to $55.00. They now have an “overweight” rating on the stock.
• 8/4/2026 – Veracyte had its price target lowered by Morgan Stanley from $47.00 to $44.00. They now have an “underweight” rating on the stock.
• 8/3/2026 – Veracyte had its price target lowered by Canaccord Genuity Group Inc. from $60.00 to $50.00. They now have a “hold” rating on the stock.
• 7/31/2026 – Veracyte had its price target raised by Needham & Company LLC from $57.00 to $69.00. They now have a “buy” rating on the stock.

Insider Transactions at Veracyte

In other Veracyte news, EVP Annie Mcguire sold 3,254 shares of the stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $43.09, for a total transaction of $140,214.86. Following the completion of the transaction, the executive vice president owned 131,160 shares in the company, valued at approximately $5,651,684.40. This represents a 2.42% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Jens Holstein sold 5,000 shares of Veracyte stock in a transaction dated Monday, September 14th. The shares were sold at an average price of $40.95, for a total value of $204,750.00. Following the completion of the sale, the director directly owned 27,471 shares in the company, valued at $1,124,937.45. This represents a 15.40% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 30,895 shares of company stock worth $1,307,448. Company insiders own 1.60% of the company’s stock.

Veracyte, Inc is a diagnostics company that develops and commercializes genomic tests designed to help physicians diagnose cancer, assess disease risk and guide treatment decisions. The company combines genomic data with bioinformatics and machine-learning technologies to provide clinically actionable information from patient tissue samples.

Veracyte’s portfolio includes Afirma tests for evaluating thyroid nodules, Decipher tests for assessing the risk and biological characteristics of prostate cancer, and Prosigna for classifying and evaluating recurrence risk in certain breast cancers.